...DMPK. AMO Pharma Ltd. is planning a pivotal trial testing small molecule GSK3B inhibitor tideglusib (AMO-02...

...models of other KRAS-driven cancers. Noscira S.A. and AMO Pharma Ltd. have the GSK3 inhibitor tideglusib...

...patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02...
...of once-daily 400 or 1,000 mg oral tideglusib. The company said most patients treated with tideglusib...
...type 1 (DM1) Endpoint: Safety Status: Phase II data Milestone: NA Jennie Walters tideglusib (AMO-02, np-12, Nypta, Zentylor) AMO...

...inhibitor in additional models of cancer and IBD. Noscira S.A. and AMO Pharma Ltd. have tideglusib...

...GSK3 inhibitors in additional lymphoma and melanoma models. Noscira S.A. and AMO Pharma Ltd. have tideglusib...

...in animal models of dyskeratosis congenita. Noscira S.A. and AMO Pharma Ltd. have tideglusib ( AMO-02...

...Ltd. , Wonersh, U.K. Noscira S.A. , Madrid, Spain Product: Tideglusib ( AMO-02 ) (formerly NP-12...

...mouse models of GBM, the GSK3β inhibitor tideglusib decreased tumor growth and increased survival, and tideglusib...
...animal models of other brain cancers. Noscira S.A. and AMO Pharma Ltd. have tideglusib ( AMO-02...

...AMO-01's primary competitors. The synthetic analog of glycine-proline-glutamate is in Phase II. AMO's second program, AMO-02...
...DM1, Steinert's disease). AMO-02, an inhibitor of glycogen synthase kinase 3 beta (GSK3B) formerly dubbed tideglusib...
...hyperphosphorylation of tau. Data reported in The Journal of Clinical Investigation in 2012 showed an AMO-02...

...inhibitor, in Phase II testing for acute leukemia and pancreatic cancer. AMO Pharma Ltd. has AMO-02...